ALBI grade has been validated for PFS and OS across the spectrum of HCC staging, but progression risk in multivariate analysis controlling for HCC burden and the AFP biomarker was restricted to the small percentage of ALBI Grade 3 patients compared to ALBI Grade 2. The gene discussed is AFP; the disease is hepatocellular carcinoma.